Beijing, Feb 6 (Prensa Latina) Chinese regulators formalized the commercialization, but under certain conditions, of the CoronaVac vaccine developed by the pharmaceutical company Sinovac Biotech to prevent Covid-19, the company itself confirmed today.
He specified that the conclusive results of the tests are not yet available and the safety and efficacy indexes must also be corroborated.
CoronaVac thus became the second vaccine against Covid-19 that China endorses to be commercialized, on a conditional basis. Earlier, the Administration gave the green light to the inactivated CNBG, a subsidiary of state-owned Sinopharm.
This will imply a strict supervision of the quality and safety of the medicine from the manufacture to the application of each dose.
The immunizer is one of four that China applied to more than 32 million citizens since last July, as part of an emerging use plan.
Investigations in Turkey yielded 91.25 percent effectiveness, in Indonesia it was 64.5 and Brazil concluded them with 50.3.
But some international press media emphasize the difference in the percentage obtained in the three cases, when criticizing the substance.
The World Health Organization evaluates Sinovac, Sinopharm, and CanSino products to determine if they meet global standards for quality and safety before they are included in the global list of approved vaccines.
However, more and more nations on the planet are closing agreements with pharmaceutical companies to obtain their substances.
China has 16 vaccine candidates against Covid-19, of which seven are in the final phase of clinical trials.
He accelerated the inoculation in the midst of the worst outbreak of the disease, which only in January left him with 2,16 autochthonous cases and two deaths.
According to the National Health Commission, the country accumulates at least 4,831 deaths and 101,241 confirmed cases of the disease in its mainland, Hong Kong, Macao and Taiwan.
In addition, it counts 733 asymptomatic patients under medical observation.